Free Trial
OTCMKTS:MRMD

MariMed Q3 2025 Earnings Report

MariMed logo
$0.16 0.00 (-0.24%)
As of 02:27 PM Eastern

MariMed EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

MariMed Revenue Results

Actual Revenue
N/A
Expected Revenue
$42.15 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MariMed Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

MariMed Earnings Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
MariMed Announces Third Quarter 2025 Earnings Date
See More MariMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MariMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MariMed and other key companies, straight to your email.

About MariMed

MariMed (OTCMKTS:MRMD) is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs. MariMed’s proprietary formulations are developed in its research and development labs, where it focuses on dosing consistency, terpene profiles and potency control. In addition to in‐house brands such as Nature’s Heritage and Lowell Farms, MariMed supplies white‐label products for third‐party operators and manages state‐licensed manufacturing facilities on behalf of other cannabis companies.

MariMed’s operations span multiple state markets, including Massachusetts, Maryland, Illinois, and Pennsylvania, where it holds cultivation and processing licenses as well as retail dispensary permits. The company’s retail banners, notably Zen Leaf, serve adult‐use and medical patients with a curated selection of cannabis products and patient education services. By aligning its facility design, cultivation practices and product offerings with state regulatory requirements, MariMed strives to maintain compliance while scaling its footprint in high‐growth cannabis markets.

Founded in 2011 by chief executive officer Bob Fireman, MariMed leverages more than a decade of experience in life‐science research, pharmaceutical formulation and regulated consumer products. Under Fireman’s leadership, the company has built a vertically integrated platform that emphasizes quality assurance, regulatory compliance and community engagement. MariMed Inc. trades on the OTC Markets under the ticker symbol MRMD and continues to pursue new licensing opportunities and strategic collaborations to broaden its cannabis enterprise.

View MariMed Profile

More Earnings Resources from MarketBeat